{"news_desk": "Business", "print_page": null, "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By NEIL UNMACK", "person": [{"rank": 1, "role": "reported", "firstname": "Neil", "organization": "", "lastname": "UNMACK"}]}, "abstract": null, "type_of_material": "News", "word_count": "338", "lead_paragraph": "The Swiss giant is putting three drugs in development into a new entity backed by investors. With biotech markets hot, there\u2019s room for copycat deals.", "pub_date": "2015-07-30T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Novartis Spinoff Shows Alternative to Big Drug Makers", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}, "snippet": "The Swiss giant is putting three drugs in development into a new entity backed by investors. With biotech markets hot, there\u2019s room for copycat deals.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/07/30/business/dealbook/novartis-spinoff-shows-alternative-to-big-drug-makers.html", "keywords": [{"rank": "1", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Biotechnology and Bioengineering", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Novartis AG", "name": "organizations"}, {"rank": "5", "is_major": "N", "value": "Mereo BioPharma Group Ltd", "name": "organizations"}], "blog": [], "_id": "55b9314c38f0d810f5649326", "source": "The New York Times"}